MDDI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

V-Go Shown to Have Improved Benefit for Insulin Patients

Valeritas Holdings has developed V-Go, a wearable insulin delivery device and presented data about the technology at the Metabolic & Endocrine Disease Summit in San Diego, CA.

There is clinical benefit from using Valeritas Holdings’ V-Go Wearable Insulin Delivery Device. The Bridgewater, NJ-based company unveiled results from a poster titled “Use of V-Go Wearable Insulin Delivery device by Advanced Practitioners Demonstrated Improved Clinical Benefits in Patients with Type 2 Diabetes Uncontrolled on Multiple Daily Injections of Insulin,” was unveiled at the Metabolic & Endocrine Disease Summit in San Diego, CA.

This study demonstrated that patients treated by Advanced Practitioners experienced improved A1c levels while lowering insulin total daily dose (TDD) after switching to V-Go from MDI of insulin. Patients in this study were evaluated after a mean duration of three and seven months. At three months, the mean change in A1c was -1.1% from the mean baseline of 9.1%, and mean insulin TDD decreased to 58 units per day from a mean baseline of 87 units per day. At seven months, the mean change in A1c was also -1.1%, while the mean insulin TDD was 61 units per day. Change in the mean weight was less than 1 kg at both time points.

“For many patients with type 2 diabetes, being able to adhere to an insulin regimen consisting of multiple daily injections is a real challenge as it can be burdensome to daily living and complex,” said Amanda Patricia Wakim, DNP, FNP-BC an endocrinology-focused nurse practitioner in Wheeling, WVA, in a release. “In my practice, V-Go has been well received by patients as it removes the need for multiple injections, is simple to use, and has enabled many of my patients to lower their glucose, use less insulin, and not gain the weight normally seen with intensified insulin therapy.”

Valeritas received a nod from FDA to market Valeritas in 2010. V-Go is an all-in-one basal-bolus insulin delivery option for patients and was designed to deliver a continuous preset basal rate of insulin over a 24 hour period, while also providing on-demand dosing at mealtimes to help patients control blood sugar levels.

The wearable doesn't require the setup of an infusion site, and instead is filled before placing on the body under the clothing. Once applied to the skin, the device inserts a small needle into the skin that can allow patients to move freely throughout the day without feeling the needle. V-Go was featured in the MD&M East’s Fashion Show: Digital Health Wearables in Action held in New York this past June.

Filed Under
500 characters remaining